Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients

Table 2 Patients' classification according Immune response

Study	Patients' classification		Anti EGF antibody titers *(Geometric mean of sera dilution)*
	GAR	SGAR
Phase II Trial (low dose, 1 injection site)	18 (52.8%)	4 (10.8%)	1:3160
Phase III trial (high dose, 4 injection sites)	22 (56.4%)	12 (30.8%)	1:7328

Patients were classified as Good Antibody Responders (GAR) if they reached an anti-EGF antibody titer ≥ 1:4000 and SGAR if they reached an anti-EGF antibody titer ≥ 1:64000.